300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: BIO-Europe Set to Break Records in Munich, Germany

EQS-News: EBD Group / Key word(s): Conference
BIO-Europe Set to Break Records in Munich, Germany

27.09.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

For Immediate Release

BIO-Europe Set to Break Records in Munich, Germany

MUNICH, GERMANY – September 27, 2023 – BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, is gearing up for its 29th edition, which is set to be the largest and most internationally diverse event to date. With current registration patterns signalling remarkable growth and a substantial increase in global participation, BIO-Europe 2023 promises to be an unparalleled opportunity for collaboration and innovation in the biopharma sector.

Scheduled to take place from November 6–8, 2023, in the vibrant city of Munich, Germany, BIO-Europe has established itself as the epicenter of biopharmaceutical partnering, attracting leaders, innovators, and decision-makers from across the world. The event is proudly organized by EBD Group and hosted on partneringONE®, a state-of-the-art digital platform that facilitates meaningful connections and collaborations.

As the countdown to BIO-Europe 2023 begins, the organizers are thrilled with the ongoing enthusiasm and support from the global biopharma community. Current registration trends indicate a substantial surge in interest, with over 5,000 delegates anticipated to convene in Munich and participate in over 27,000 one-to-one meetings to drive life science global dealmaking to new levels. Additionally, the event will feature three days of program sessions; attendees will learn the important trends and opportunities in the life sciences from some of the brightest minds in the sector. The agenda has been built around three themes: the Business of Biotech, Therapeutic Insights, and Ecosystem Innovation.  

In addition to the main event, BIO-Europe is extending its reach further by hosting digital partnering days on November 14–15, 2023, which will be accessible through partneringONE®. These days will welcome an additional opportunity for participants to connect, collaborate, and explore potential partnerships.

"Each year, BIO-Europe raises the bar for what a biopharmaceutical partnering event can achieve. The overwhelming response from the global life sciences industry is a testament to the event's reputation as your 'gateway to the global biopharma community,’” said Claire Macht, European Portfolio Director for EBD Group. “We are thrilled to witness the continued growth and international appeal of BIO-Europe, and we look forward to welcoming over 5,000 delegates to Munich. Together, we will catalyse innovation, foster collaborations, and accelerate the biopharma industry forward."

partneringONE® is now open! Registered attendees are already busy scheduling their one-to-one meetings. Register today to secure your spot at BIO-Europe 2023 and unlock endless possibilities for collaboration and growth.

BIO-Europe is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).  

For more information, please visit the conference website at:   

Additional links and information: 

Follow BIO-Europe 2023 on X (formerly Twitter) (hashtag: #BIOEurope) or on . 

About EBD Group 

EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, ChinaBio® Partnering Forum, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. EBD Group is an Informa company. For more information, please visit .

Media Contacts:
MC Services AG 
 
  

Karina Marocco
EBD Group



27.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


1733889  27.09.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1733889&application_name=news&site_id=research_pool
EN
27/09/2023

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch